Filtered By:
Source: Cancer Research
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 807 results found since Jan 2013.
Abstract 5113: Rapid Cancer Imaging By GGT-targeted Fluorescence Probe For Primary Lung Cancer
IntroductionLung cancer is the leading cause of cancer death in Japan, however, it has been difficult to detect and diagnose precisely lung cancer with a diameter less than 1cm to date. The purpose of this study is to investigate clinical application of novel GGT-targeted fluorescence probe for detecting the primary lung cancer in an intraoperative manner.MethodsAs a fluorescence probe for γ-glutamyltranspeptidase (GGT), γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) was used. gGlu-HMRG is non-fluorescent, but is converted to a highly fluorescent hydroxymethyl rhodamine green (HMRG) upon reaction with the enzyme, w...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Hino, H., Kawashima, M., Murayama, T., Ichinose, J., Kitano, K., Nagayama, K., Nitadori, J.-i., Anraku, M., Murakawa, T., Mizuno, K., Tanaka, S., Kamiya, M., Nishiyama, N., Kataoka, K., Miyazono, K., Urano, Y., Nakajima, J. Tags: Tumor Biology Source Type: research
Abstract 5213: RUNX2 modulates the angiogenic potential of human neuroblastoma cells
In conclusion, our study suggests that hypoxia upregulates RUNX2 expression in NB1691 cells and knockdown of RUNX2 decreases the angiogenic potential of hypoxic NB1691 cells.Citation Format: Manu Gnanamony, Indra Mohanam, Sanjeeva Mohanam. RUNX2 modulates the angiogenic potential of human neuroblastoma cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5213. doi:10.1158/1538-7445.AM2015-5213
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Gnanamony, M., Mohanam, I., Mohanam, S. Tags: Tumor Biology Source Type: research
Abstract 5400: A novel combinatorial therapy for hepatocellular carcinoma (HCC)
The incidence of hepatocellular carcinoma (HCC) is rising in the US with parallel increase in mortality rate. Lack of effective therapy for advanced HCC mandates development of novel targeted therapies to counteract this fatal malady. Astrocyte elevated gene-1 (AEG-1), also known as metadherin (MTDH) and LYRIC, plays a pivotal role in hepatocarcinogenesis and serves as an ideal target for anti-HCC therapy. AEG-1 interacts with retinoid X receptor (RXR) and inhibits retinoic acid-induced gene expression and cell death. Retinoic acid has been evaluated for HCC treatment without promising result. Overexpression of AEG-1 might...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Srivastava, J., Rajasekaran, D., Siddiq, A., Gredler, R., Robertson, C. L., Akiel, M. A., Shen, X.-N., Ebeid, K. A. N., Salem, A. K., Fisher, P. B., Sarkar, D. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5429: Inhibition of SMARCA2: a novel target for SMARCA4-deficient lung adenocarcinoma
Conclusion: SMARCA2 has been validated by our work and others as a target in SMARCA4 deficient lung adenocarcinoma. Future work will focus on elucidating the role of the bromodomain and the ATPase domain in SMARCA2/4 activity, and we are actively pursuing the identification of small molecule inhibitors of SMARCA2. An HTS has been undertaken against a library of>700 million compounds in a DNA-encoded library to identify novel hit matter that may ultimately be developed for therapeutic value.Citation Format: Phil Chapman, Nikki March, Graeme Thomson, Emma Fairweather, Samantha Fritzl, James Hitchin, Nicola Hamilton, Allan Jo...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Chapman, P., March, N., Thomson, G., Fairweather, E., Fritzl, S., Hitchin, J., Hamilton, N., Jordan, A., Waddell, I., Ogilvie, D. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5466: Integrative TCGA analyses identify Basonuclin1 (BNC1) as a key mediator for platinum resistance
Conclusion. Collectively, BNC1 represents an important target for enhancing platinum-sensitivity in ovarian and lung cancer. Targeting BNC1 in platinum-resistant malignancies may improve patient survival.Note: This abstract was not presented at the meeting.Citation Format: Sherry Y. Wu, Justyna Filant, Michael McGuire, Rajesha Rupaimoole, Sunila Pradeep, Anna Unruh, Herbrich Shelley, Cristina Ivan, Ruder Dennis, Cristian Rodriguez-Aguayo, Vasudha Sehgal, Takahito Miyake, Archana Nagaraja, Kshipra Gharpure, Guillermo Armaiz, Rebecca Previs, Gabriel Lopez-Berestein, Prahlad Ram, Keith Baggerly, Anil Sood. Integrative TCGA an...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Wu, S. Y., Filant, J., McGuire, M., Rupaimoole, R., Pradeep, S., Unruh, A., Shelley, H., Ivan, C., Dennis, R., Rodriguez-Aguayo, C., Sehgal, V., Miyake, T., Nagaraja, A., Gharpure, K., Armaiz, G., Previs, R., Lopez-Berestein, G., Ram, P., Baggerly, K., So Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5547: Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the inhibition of Wnt/{beta}-catenin signaling pathway via axin turnover in colon cancer cells
Abnormal activation of the canonical Wnt/β-catenin pathway and up-regulation of the β-catenin/T-cell factor (TCF) response to transcriptional signaling play critical roles early in colorectal carcinogenesis. Therefore, the Wnt/β-catenin signaling is considered an attractive target for cancer chemotherapeutic of chemopreventive agents, natural compounds were evaluated for β-catenin-mediated transcriptional activity. Hydnocarpin (HC), a natural lignan from Lonicera japonica was identified as a promising candidate because it effectively inhibited β-catenin/TCF reporter gene (TOPflash) activity. HC also exhibited potent g...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: KIM, W. K., LEE, M. A., PARK, H. J., HONG, J.-Y., KANG, S. S., LEE, S. K. Tags: Cancer Chemistry Source Type: research
Abstract A1-05: Elucidation of epigenetic driver genes in clear cell renal cell carcinoma using a newly developed assay, AcceSssIble
Conclusions: Our study revealed a vast number of chromatin accessibility and accompanying gene expression changes that occur in gene promoters in the development of ccRCC, both dependent and independent of DNA methylation changes. Each individual tumor has a unique profile of epigenetic alterations. Moreover, almost none of the genes that were found to undergo epigenetic and resulting gene expression changes overlap with TCGA's findings of commonly mutated genes in ccRCC. Overall, these studies represent novel approaches that can help identify new therapeutic target genes and treatment strategies for ccRCC, including perso...
Source: Cancer Research - November 15, 2015 Category: Cancer & Oncology Authors: Becket, E. C., Duymich, C., Chang, Y.-W., Pandiyan, K., Nichols, P., Jones, P., Gill, I., Liang, G. Tags: Cancer Genomics and Epigenomics Source Type: research
Abstract PD2-06: Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer
Conclusions: These data support a critical role of PDK1 in mediating acquired resistance to CDK4/6 inhibitors in ER+ breast cancer cells. Co-targeting of the PDK1 and CDK4/6 pathways may overcome resistance to CDK4/6 inhibitors and is worthy of further translational and clinical investigation in patients with ER+ breast cancer.Citation Format: Jansen VM, Bhola NE, Bauer JA, Formisano L, Moore P, Koch J, Arteaga CL. Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Anton...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Jansen, V., Bhola, N., Bauer, J., Formisano, L., Moore, P., Koch, J., Arteaga, C. Tags: Poster Discussion Abstracts Source Type: research
Abstract P5-03-13: The anticancer effects of Supinoxin(R) (RX-5902) in triple-negative breast cancer MDA-MB-231 through phosphorylated p68 on Tyr593
In this study, we sought to determine whether phosphorylated p68 on Tyr593 plays a key role in RX-5902's ability to inhibit cancer cell growth by knocking down p68. p68-siRNA efficiently down-regulated the expression of phosphorylated p68 on Tyr593 as well as p68 in the triple-negative (TN) breast cancer cell line, MDA-MB-231. Exposure of p68-siRNA-transfected cells to the IC50 concentration of RX-5902 protected MDA-MB-231 cells from the cytotoxic effects of RX-5902, indicating the phosphorylated p68 on Tyr593 is a key molecule for RX-5902 cytotoxic effects. We also examined the tumor growth inhibition (TGI) of RX-5902 in ...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Kim, D., Yang, M., Lee, Y., Remenyi, J., Fuller-Pace, F. Tags: Poster Session Abstracts Source Type: research
Abstract P5-04-13: Pin1 negatively impacts Smad3 tumor suppression in triple negative breast cancer cell lines
Conclusions: Inhibiting the Smad3-Pin1 interaction by knock-down of Pin1 expression in TNBC cells restored Smad3 transcriptional activity, which correlated to an increase in expression of the Smad3 associated protein cdki p15, decrease in c-myc, and a decrease in cellular proliferation. Additionally, Pin1 KD enhanced Smad3 protein levels, suggesting a role of Pin1 in mediating Smad3 stability. Inhibiting the Smad3-Pin1 interaction with Pin1 KD or CDK2 inhibitor treatment also reduced TNBC cell migration. Collectively, these data suggest that the Smad3-Pin1 interaction, facilitated by noncanonical CDK-mediated Smad3 phospho...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Thomas, A., Hamdan, R., Hong, A., Rosenthal, E., , Jeruss, J. Tags: Poster Session Abstracts Source Type: research
Abstract PR07: Dissection of cancer cells extravasation through human vascularized 3D microfluidic model: The major role of talin-1
Cancer cells spread from a primary tumor to secondary loci is responsible for more than 90% of cancer related mortality. Hematogenous metastasis is a complex process [1]. It includes a chain of events that can be summarized as follows: migration from primary tumor site and intravasation of the primary tumor cancer cells into the blood flow, dissemination through the circulation, extravasation in different organs, survival in the new microenvironment and colonization with generation of a new tumor.Recently our group presented a microfluidic 3D model reproducing the effects of the CXCL5-CXCR2 interaction between bone cells a...
Source: Cancer Research - May 25, 2016 Category: Cancer & Oncology Authors: Gilardi, M., Bersini, S., Kamm, R. D., Moretti, M., Vanoni, M. Tags: Circulating Evidence of Tumor Metastasis Source Type: research
Abstract C05: Pulmonary laminin 332 in tumor cell migration and breast cancer survival
Metastasis to the lung often leads to the demise of the patient, thus a greater understanding of the process might lead to strategies for better cancer control. Tumor cell metastatic ability is determined by both intrinsic properties of tumor cells and contributions from the microenvironment. The goal of this study was to determine the role of the extracellular matrix protein laminin 332 (LN332) in breast cancer progression. Because tumor cell motility is a requirement for metastasis, we hypothesize that lung tissue harbors substances that induce tumor cell migration. In order to better characterize the interaction of brea...
Source: Cancer Research - July 27, 2016 Category: Cancer & Oncology Authors: Carpenter, P. M., Sivadas, P., Ziogas, A., Anton-Culver, H. Tags: Tumor Microenvironment and Metastasis Source Type: research
Abstract A41: GPRC5A acts as a potent oncogene in pancreatic cancer
Conclusions: Our results indicate that GPRC5A acts as an oncogene in pancreatic cancer. Unexpectedly, gemcitabine was found to increase GPRC5A's mRNA and protein levels. We showed that this increase is mediated by HuR, a known enabler of gemcitabine efficacy, through a direct interaction between HuR and GPRC5A’s mRNA. It appears that the sensitivity of pancreatic cancer cells to gemcitabine can be augmented through down-regulation of GPRC5A.Citation Format: Honglei Zhou, Aristeidis Telonis, Yi Jing, Masaya Jimbo, Fernando Blanco, Eric Londin, Jonathan Brody, Isidore Rigoutsos.{Authors}. GPRC5A acts as a potent oncogene i...
Source: Cancer Research - December 13, 2016 Category: Cancer & Oncology Authors: Honglei Zhou, Aristeidis Telonis, Yi Jing, Masaya Jimbo, Fernando Blanco, Eric Londin, Jonathan Brody, Isidore Rigoutsos Tags: Early Detection Source Type: research
Abstract B57: RNAi Nanotechnology for Cancer Target Validation and Therapy
RNA interference (RNAi) represents a promising strategy for identification and validation of putative therapeutic targets, and for treatment of a myriad of important human diseases including cancer. The ubiquitous application of RNAi in cancer research and therapy is nevertheless hindered by the challenge of effective systemic in vivo delivery of RNAi agents (e.g., siRNA) to solid tumors, which requires overcoming of multiple physiological barriers, such as enzymatic degradation, rapid elimination by renal excretion or by the mononuclear phagocyte system (MPS), poor tumor penetration, and insufficient cellular uptake and e...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jinjun Shi Tags: Tumor Immunology/Immunotherapy Source Type: research
Abstract P1-08-03: Identification and characterization of a novel endoxifen substrate, PKC{beta}1, and its interaction with the estrogen receptor
Conclusions: Our findings demonstrated that endoxifen binds and inhibits PKCβ1 at relevant concentrations achieved in the endoxifen clinical trial studies. PKCβ1 interacts with cytoplasmic ERα and PKCβ1 knockdown inhibits cell proliferation and enhances ERα turnover. However, in PKCβ1 overexpressing cells, PKCβ1 may exhibit tumor suppressive effects. These data suggest a complex interaction between PKCβ1 and ERα and that endoxifen's effects on PKCβ1 may alter drug response of endocrine therapy. Further studies are ongoing to characterize the role of PKCβ1 and its role in ER biology and response to endoxifen.Cita...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: C Guo, MJ Kuffel, RA Kudgus, Z Huang, AM Bode, J Cheng, VJ Suman, JM Reid, ES Bruinsma, M Subramaniam, MM Ames, JR Hawse, MP Goetz Tags: Poster Session Abstracts Source Type: research
